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below the superior and inferior extents of the target volume. For 
patients that received planning CT scans both immediately 
before and after rectal tube insertion, treatment plans were 
generated retrospectively with matched rectal D2cc. The 
resulting plans were compared visually, and the dose received by 
the HR-CTV D90 was compared. 
Results: All patients were treated with a combination of external 
beam radiotherapy to the pelvis and 3-5 fractions of high-dose 
rate interstitial brachytherapy in twice daily fractions. Ten and 
19 patients were treated without and with a rectal tube 
respectively. Rectal volume between the first and third fractions 
was significantly more reproducible in the rectal tube group (p = 
0.038). There was a significant increase in the HRCTV D90 with 
the use of a rectal tube (mean HRCTV D90 99.5% in the non-rectal 
tube group and 106% in the rectal tube group, p = 0.002). There 
was no significant difference in the D2cc rectum between the 
two groups (p = 0.77). Seven patients received a planning CT 
immediately prior to and immediately after rectal tube 
insertion, and plans with matched rectal doses were generated 
(11 pairs of plans). For these patients there was no significant 
difference in the HRCTV D90 between the rectal tube and no 
rectal tube plans (p = 0.187). There were seven plans in which 
the use of a rectal tube increased the HRCTV D90, and four plans 
in which it lowered the HRCTV D90. On visual inspection of these 
plans the rectal tube appeared to push the rectal wall anteriorly. 
Conclusions: For the patients included in this study, the use of 
a rectal tube in ISBT significantly reduced variability in rectal 
volume between the first and third treatment fractions. Overall 
the use of a rectal tube was associated with a significantly 
increased dose to the HRCTV D90, and no significant change in 
the D2cc to the rectum. However, for some patients the use of a 
rectal tube may worsen dosimetric parameters if the rectum is 
pushed anteriorly towards the target volume by the relatively 
stiff rectal tube. Further work is required in identifying patients 
who may not benefit from use of a rectal tube. 
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Purpose: Brachytherapy (BT) techniques for cervical cancer (CC) 
in Canada have changed over the last decade, with evolution to 
HDR and image-guided BT. However, there are currently no 
national data on the use of interstitial BT (IBT) in the 
management of patients with CC. The purpose of this study was 
to document IBT utilization in Canadian centres, as well as 
update details of CC BT practices. 
Methods and Materials: All Canadian centres with gynecologic 
BT services (n = 32) were identified, and one gynecology 
radiation oncologist per centre was sent a 33-item e-mail 
questionnaire regarding the centre’s practice for CC BT in 2015. 
Responses are reported and compared with practice patterns 
identified in a 2012 Canadian survey.  
Results: The response rate was 81% (26 of 32 centres). The 
majority (92%) used high-dose rate (HDR) BT, identical to the 
2012 survey. Ninety-three percent (24 of 26) of centres had 
transitioned to 3D MRI/CT based planning by 2015, versus 80% in 
2012. Sixty-five percent of centres incorporated MRI for 
treatment planning in 2015 compared to 37% in 2012; the 
majority (13/16) using a combination of MRI and CT. Fifty 
percent (13 of 26 centres) had the capacity to perform IBT; in 
those that did not, 50% referred patients to other centres who 
performed the procedure. Of centres performing IBT, the 
majority (nine out of 13) used free-hand template-based 
techniques. For IBT, a median of five (range 2-20) 
needles/catheters was used and an average of four (range 1-5) 
fractions were delivered. Catheters were placed using a variety 
of image-guidance modalities: pre-op imaging (54%), intra-op 
MRI (8%), intra-op CT (23%), and intra-op U/S (46%). The majority 
(77%) of centres performing IBT used inverse planning 
techniques. The most common dose/fractionation schedules 
were 6 Gy x 5 fractions (40%), 8 Gy x 3 fractions (19%) and 7 Gy 
x 4 fractions (15%). 
Conclusions: In Canada, treatment of cervical cancer continues 
to evolve. Interstitial BT has been adopted by half of the 
responding centres. As more centres move to MRI-based image-
guided treatment planning, IBT will become an even more 
integral part of cervical cancer treatment. 
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Purpose: Risk stratification for localized prostate cancer can 
assist clinicians select the most appropriate treatment for their 
patients based on baseline clinical factors. The present study 
aimed to externally validate a recently published nomogram for 
low-dose rate (LDR) brachytherapy that was developed in 
patients treated in several Canadian centers. 
Methods and Materials: Patients receiving LDR brachytherapy at 
the Centre Hospitalier de l’Université de Montréal (CHUM) for 
localized prostate cancer between 2005 and 2015 and with a 
minimum of six months of follow up were eligible for analysis (n 
= 903). External validation was performed on the ProCaRS 
nomogram for LDR-brachytherapy to predict five-year 
biochemical failure free survival (BFFS). This was performed 
using calibration plots of nomogram predicted probability 
compared to corresponding Kaplan-Meier five-year BFFS 
estimates. 
Results: Mean age of the validation cohort was 65 years and 
median baseline PSA was 5.5 ng/mL. All patients had T1 (75%) or 
T2 (25%) disease and most had either Gleason 6 (70%) or Gleason 
7 (29%). Mean D90 was 161 Gy (standard deviation [SD] 25) and 
10% of patients received D90 < 130 Gy. Reasonable nomogram 
calibration was observed (R2 = 0.778), however this produced an 
underestimation of the true survival for all values based on the 
point estimates, particularly for nomogram predicted survival < 
90% and 92-94%. This finding may be partially attributed to the 
limited number of patients with observed BFFS < 90% and a 
shorter follow up in the CHUM compared to the original cohort 
used to develop the nomogram. A sensitivity analysis was 
performed to determine an adjustment to the nomogram 
predicted probability to improve calibration. Applying an 
adjustment of +3.24% to the nomogram predicted probability 
yielded a more favourable calibration for both nomograms 
(adjusted R2 = 0.813). 
Conclusions: We believe the LDR brachytherapy ProCaRS 
nomogram is a clinically useful tool that may help clinicians in 
treatment selection and outcome prediction for prostate cancer. 
For instance, it may be useful in counseling patients with 
intermediate-risk cancers that may benefit from exclusive LDR 
brachytherapy. 
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